[Cytogenetic alterations in meningioma tumors and their impact on disease outcome].
In recent years important advances have been achieved in the understanding of the genetic abnormalities present in meningioma tumors and its association with the ontogeny and progression of these tumor. Accordingly, while the presence of monosomy 22/22q-, associated with mutation of the NF2, BAM22, RRP22, GAR22, MN1, SMARCB1, CLH22 and/or LARGE genes, is associated with neoplasic transformation, other alterations such us monosomy 14, del(1p), different chromosomal abnormalities localized at 9p, 10q and 17q and complex karyotypes are frequently related to tumor progression. From the clinical point of view, currently available information about the impact of the different cytogenetic abnormalities on disease behavior and patient outcome is still scanty; nevertheless, the presence of gains of chromosome 22 in the context of a hyperdiploid karyotype, as well as del(1p) and monosomy 14 have been associated with a statistically significantly shorter recurrence-free survival, this later abnormality showing an independent prognostic value.
Sayagués
José María
JM
Servicio General de Citometría, Departamento de Medicina y Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, España. ppmari@usal.es
Tabernero
María Dolores
MD
Maíllo
Angel
A
D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D006801:Humans; D008577:Meningeal Neoplasms / Q000235:genetics* / Q000473:pathology*; D008579:Meningioma / Q000235:genetics* / Q000473:pathology*; D011379:Prognosis